Gastroenterology and Hepatology

Episodes 1-5 of 5

• 

  MinuteCE®

  Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making  

  0.50 credits 4 episodes

  • 

    

    James M. Cleary, MD, PhD

  0.50 credits 4 episodes

• 

  RestartResume

  Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers

  RestartResume

  Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers

  MinuteCE®

  Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers

  0.50 program credits

  • 

    

    James M. Cleary, MD, PhD

  0.50 program credits

• 

  RestartResume

  Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers

  RestartResume

  Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers

  MinuteCE®

  Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers

  0.50 program credits

  • 

    

    James M. Cleary, MD, PhD

  0.50 program credits

• 

  RestartResume

  Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer

  RestartResume

  Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer

  MinuteCE®

  Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer

  0.50 program credits

  • 

    

    James M. Cleary, MD, PhD

  0.50 program credits

• 

  RestartResume

  Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  

  RestartResume

  Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  

  MinuteCE®

  Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers  

  0.50 program credits

  • 

    

    James M. Cleary, MD, PhD

  0.50 program credits